Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 2022

View Archived Issues

ADAM10 may be a promising therapeutic target for AML

Sunshine Lake Pharma patents new GCGR and/or GLP-1 receptor agonists

Eubulus Biotherapeutics discloses new GPX4 inhibitors

Roche presents new EGFR mutant inhibitors

Reistone Biopharma divulges new CatC inhibitors

Palacky University patents new terpenoid derivatives

Novel mouse models of BrafV600E-driven thyroid tumors

Alaunos and NCI extend CRADA to assess use of Sleeping Beauty technology for TCR T-cell therapy

Ascentage receives IND clearance for first-in-human study of EED inhibitor APG-5918

HNSCC treatment should focus on targeting TSPAN1

Generian and Mitobridge collaborate to discover and develop small molecules for undruggable targets

Tumors might be nudged to more treatable state

IAMA reports responses with selective NKCC1 inhibitors in animal models of Down syndrome and autism

Anti-VISTA monoclonal antibody KVA-12.1 produces antitumor responses in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...